"Pritelivir for HSV-2 Genital Infections"

Filed under Research

http://www.jwatch.org/na33273/2014/01/15/pritelivir-hsv-2-genital-infections

Nucleoside analogues, which inhibit herpes simplex virus (HSV) DNA polymerase following phosphorylation by the viral thymidine kinase, have been a mainstay in the treatment and prevention of genital HSV-2 infections. These agents have limitations, however, including development of resistance and inability to reduce viral shedding. Pritelivir, the first in a new class of antiviral agents, inhibits HSV replication by targeting the viral helicase–primase complex. It has shown potent in vitro activity, as well as efficacy in infection models; phase I studies have demonstrated no safety issues. Now, in an industry-sponsored, proof-of-concept study conducted at seven sites in the U.S., researchers have evaluated the effect of various doses of pritelivir in reducing the HSV-2 shedding rate.